通络救脑口服液对实验性类AD大鼠血清细胞因子含量的影响

Expression of TNFa and IL-β1 in Aβ1-40 Induced AD in Rats and the Effect of TLJN Oral Solution

目的探讨大鼠大脑海马立体定向注射β-淀粉样蛋白1-40对血清TNF-α和IL-1β含量的影响及通络救脑口服液对其干预作用。方法140只Sprague-Dawley（SD）大鼠随机分为空白对照组、假手术组、阴性对照组、阳性对照组、实验组（12,24,48 mg·kg^-1·d^-1）共7组。采用大脑海马立体定向注射β-淀粉样蛋白1-40诱导Alzheimer＇s病动物模型后,药物干预4周,第5周应用双抗夹心酶联免疫吸附测定检测TNF-α和IL-1β含量。结果模型组TNF-α,IL-1β含量分别为（120.97±7.32）和（88.54±4.07）,TNF-α和IL-1β含量显著多于假手术组（TNF-α为85.43±6.55,IL-1β为68.29±4.37,P〈0.01）,表明模型组TNF-α和IL-1β含量升高;与模型组比较,盐酸多萘哌齐组（TNF-α为106.86±7.09;IL-1β为1.80±0.23）、通络救脑口服液12,24,48 mg·kg^-1·d^-1剂量组（TNF-α分别为100.08±9.29、99.97±6.09和85.90±4.40;IL-1β分别为（77.56±6.97）,（77.85±3.81）和（67.87±2.38）TNF-α和IL-1β含量升高显著减少。结论大鼠海马注射β-淀粉样蛋白1-40后大鼠血清TNF-α和IL-1β含量明显增高,通络救脑口服液可以降低血清TNF-α和IL-1β的含量,从而发挥其抗老年性痴呆的作用。

Objective To observe the effect of TLJN Oral Solution on express level of TNF-α and IL-1β in serum of experimental AD rats in vivo. Methods 140 SD rats were enrolled in the study, and they were equally randomly divided into blank control group ,sham control group,negative control group,positive control group and experiment group（48,24,12mg·kg^-1·d^-1）. A rat model of AD was induced by amyloid-β1-40 sterotaxis injection into the bilateral Hippocampus. All rats were sacrificed at the 5 th week after treatment for 4 weeks. TNFα and IL-1 β protein levels in serum were determined using ELISA. Results Protein levels of TNF-α and IL-1β in serum were raised in model groups, in which TNF-α were 85.43 ±6.55 and IL - 1β were 68. ：29 ± 4.37, compared with the sham group（ TNF-α were 85.43 ± 6.55 , IL-1 β were 68.29 ± 4.37） ,P 〈 0.01. In experiment groups , which TNF-α respectively were （ 100.08 ± 9.29）, （99.97 ± 6.09） and （ 85.90 ± 4.40） , and IL-1 β respectively were （77.56 ± 6.97 ）, （77.85 ± 3.81 ） and（67.87 ± 2.38 ）, protein levels of TNF-α and IL-1 β were reduced compared with the model group （ P 〈0.01 ）. Conclusion TLJN Oral Solution can reduce TNF-α and IL-1β content in serum.